NUWE · XBRL financial data

Nuwellis financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NUWE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Revenue from contracts with customers	2,412	2,551*	1,857	2,194	2,367	2,322*	1,904	1,725	2,217	2,424*	2,403	1,969
Cost of goods and services sold	1,031	1,163*	666	720	711	967*	837	767	772	770*	719	471
Gross profit	1,381	1,388*	1,191	1,474	1,656	1,355*	1,067	958	1,445	1,654*	1,684	1,498
Research and development	1,117	1,372*	1,334	558	486	831*	550	675	603	884*	1,728	942
Selling, general and administrative	3,428	3,609*	4,606	3,236	2,702	2,911*	3,577	3,189	3,539	3,213*	4,524	3,725
Total operating expenses	4,545	4,981*	5,940	3,794	3,188	3,742*	4,127	3,864	4,142	4,097*	6,252	4,667
Operating income (loss)	(3,164)	(3,593)*	(4,749)	(2,320)	(1,532)	(2,387)*	(3,060)	(2,906)	(2,697)	(2,443)*	(4,568)	(3,169)
Other income (expense)	(204)	56*	(101)	6	8	7*	7	10	4	(11)*	1	7
Income tax expense (benefit)	2	2*	2	2	0	1*	1	4	0	0*	0	0
Net income (loss)	(3,370)	(5,509)*	(4,330)	(7,725)	2,358	(1,468)*	(3,014)	(12,553)	468	(2,422)*	(4,541)	(4,828)
Earnings per share, basic‡ USD per share	(3,317,059.58)	—	(1,099,577.76)	(967,261.90)	89,285.71	—	(1,026.79)	(2,178.21)	20.00	—	(78.21)	(26.64)
Earnings per share, diluted‡ USD per share	(3,317,059.58)	—	(1,099,577.76)	(967,261.90)	89,285.71	—	(1,026.79)	(2,178.21)	20.00	—	(78.21)	(26.64)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	3	6	23	—	58	181
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	3	6	23	—	58	181

‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-34.48275862068965 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-41.666666666666664 stock split (July 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2026); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 35x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 49x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (NUWE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	4,930	3,800	1,400	1,023	1,907	5,095	2,557	4,450	3,094	1,085	2,083	3,922
Marketable securities	0	0	—	—	—	—	—	—	—	—	—	—
Accounts receivable	1,425	1,951	1,226	1,292	1,293	1,727	1,540	1,193	1,141	1,493	1,559	1,545
Inventory	2,336	1,997	2,131	1,967	1,864	1,718	1,752	2,028	2,189	1,910	1,779	1,742
Total current assets	9,638	8,209	5,197	4,826	5,494	8,855	6,123	8,416	7,200	5,186	5,827	7,899
Property and equipment, net	912	728	681	630	551	478	405	359	414	368	365	347
Right-of-use asset	762	713	664	613	563	510	457	404	349	293	237	179
Total assets	11,432	9,770	6,662	6,189	6,728	9,864	7,006	9,200	7,984	6,118	6,961	9,126
Total current liabilities	2,992	3,172	4,323	4,016	2,701	2,559	2,749	3,892	3,522	3,032	3,730	4,008
Lease liability, non-current	601	544	488	428	368	307	249	189	128	67	0	0
Total liabilities	3,593	6,559	5,775	13,023	3,549	3,334	3,424	18,155	4,070	3,488	4,292	11,171
Accumulated deficit	(282,117)	(287,626)	(291,956)	(299,681)	(297,323)	(298,791)	(301,805)	(314,358)	(313,890)	(316,312)	(320,853)	(325,681)
Total stockholders' equity	7,839	2,990	885	(6,836)	3,177	6,528	3,578	(8,960)	3,908	2,624	2,661	(2,055)
Total liabilities and equity	11,432	9,770	6,662	6,189	6,728	9,864	7,006	9,200	7,984	6,118	6,961	9,126
Common shares outstanding (cover page)‡ thousands of shares	0	0	0	0	0	3	3	25	46	65	75	3,647

‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-34.48275862068965 stock split (June 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-41.666666666666664 stock split (July 2025); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-35.714285714285715 stock split (June 2026); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 35x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 49x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (NUWE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(3,370)	(5,509)*	(4,330)	(7,725)	2,358	(1,468)*	(3,014)	(12,553)	468	(2,422)*	(4,541)	(4,828)
Stock-based compensation	135*	157*	158	115*	101*	104*	67	17*	19*	24*	25	22*
Depreciation and amortization	84*	—	—	—	—	—	—	—	—	—	—	—
Net cash from operating activities	(3,825)*	(2,754)*	(2,862)	(2,754)*	(2,471)*	(1,504)*	(2,536)	(2,097)*	(3,147)*	(3,030)*	(3,112)	(3,175)*
Purchases of property and equipment	121*	(36)*	29	24*	(16)*	23*	0	4*	98*	(12)*	30	9*
Net cash from investing activities	(121)*	36*	(29)	(24)*	16*	(23)*	0	(4)*	(98)*	12*	(284)	(9)*
Proceeds from issuing common stock	0*	—	—	—	0*	0*	0	3,999*	0*	0*	4,393	—
Net cash from financing activities	(20)*	1,595*	500	2,403*	3,343*	4,716*	0	3,999*	1,889*	1,052*	4,395	5,023*
Net change in cash	(3,966)*	(1,130)*	(2,400)	(377)*	884*	3,188*	(2,538)	1,893*	(1,356)*	(1,904)*	999	1,839*

† Share count changed about 2x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 35x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 49x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nuwellis	3,922	1,969	(3,175)*	3.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Glucotrack	1,124	not reported	(3,616)*	10.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Catheter Precision	643	1,019	(2,861)*	14.4M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Aethlon Medical	4,934	not reported	(1,897)	711,136	2.6 quarters	Q1 FY27 10-QJun 30, 2026
STRATA Skin Sciences	7,912	9,292*	(239)*	5.9M	33.1 quarters	Q4 FY25 10-KDec 31, 2025
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
Odyssey Health	122	not reported	(160)*	110.2M	0.8 quarters	Q4 FY26 10-KJul 31, 2026
Autonomix Medical	3,460	0	(3,544)	971,043	1.0 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.